Viatris Inc. (Viatris) is a healthcare company. The Company operates through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan, and Hong Kong. The JANZ segment includes its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its operations in Asia, the Middle East, South and Central America, Africa, and Eastern Europe, and also includes the Company’s anti-retroviral franchise. The Company's portfolio comprises of approximately 1,400 approved molecules across a range of key therapeutic areas including generic, complex generic, and biosimilar products. The Company operates approximately 50 manufacturing sites worldwide that produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients (APIs).